MET and cancer: The main challenges facing the effective use of HGF/MET-targeted agents for cancer treatment are optimal patient selection, diagnostic and pharmacodynamic biomarker development, the identification and testing of rational drug combinations and further understanding of the toxicities associated with pathway inhibition.